author-photo

J. Greg Slatter

Amgen

32

Papers

674

Citations

Citation Trend

Filter By

Papers (24) Sort By

Journal Conference Others

Phase 1 Concentration-QTc and Cardiac Safety Analysis of the MDM2 Antagonist KRT-232 in Patients With Advanced Solid Tumors, Multiple Myeloma, or Acute Myeloid Leukemia.

2021 Clinical pharmacology in drug development
Show All
- Source
- Cite
- Save
Citations (0)
P170 - Microtracer bioavailability, biotransformation mechanisms, and excretion of the covalent BTK inhibitor acalabrutinib in humans

2020 Drug Metabolism and Pharmacokinetics
Show All
- Source
- Cite
- Save
Citations (0)
A Mechanistic Physiologically Based Pharmacokinetic (PBPK) Drug Interaction Model for the Mouse Double Minute 2 (MDM2) Inhibitor KRT-232

2020 Blood
Show All
- Source
- Cite
- Save
Citations (1)
Effect of Food on MDM2 Inhibitor KRT-232 Pharmacokinetics and Macrophage Inhibitory Cytokine-1 (MIC-1) Response in Healthy Volunteers

2020 Blood
Show All
- Source
- Cite
- Save
Citations (1)
Evaluation of the Drug‐Drug Interaction Potential of Acalabrutinib and its Active Metabolite, ACP ‐5862, Using a PBPK Modeling Approach

2019
Show All
- Source
- Cite
- Save
Citations (14)
Abstract 2194: Preclinical pharmacological profiling of ACP-5862, the major metabolite of the covalent BTK inhibitor acalabrutinib, displays intrinsic BTK inhibitory activity

2019 Cancer Research
Show All
- Source
- Cite
- Save
Citations (2)
Population Pharmacokinetics of the BTK Inhibitor Acalabrutinib and its Active Metabolite in Healthy Volunteers and Patients with B-Cell Malignancies

2019 Clinical Pharmacokinectics
Show All
- Source
- Cite
- Save
Citations (7)
Bridging in vitro dissolution and in vivo exposure for acalabrutinib. Part II. A mechanistic PBPK model for IR formulation comparison, proton pump inhibitor drug interactions, and administration with acidic juices

2019 European Journal of Pharmaceutics and Biopharmaceutics
Show All
- Source
- Cite
- Save
Citations (14)
Efficacy and Safety of Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma in the Phase 2 ACE-LY-004 Study

2017 Blood
Show All
- Source
- Cite
- Save
Citations (3)
CYP3A-Mediated Drug Interaction Profile of Bruton Tyrosine Kinase Inhibitor, Acalabrutinib

2017 Blood
Show All
- Source
- Cite
- Save
Citations (4)